12.06.19
5 min. read

Sanofi’s in-house DTx. 1,162 clinical trials used digital tools in 2018.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 030.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 62 percent open rate. Here's what's happening this week:

  • My backyard now features both a seven-foot-tall snowman and his companion snowdog, following the Greater Boston area's first snowstorm of the season.
  • Foley's telemedicine report focused on commercial payer laws throughout the US is well worth a read.
  • Nothing new but... in his first interview since assuming the post in July, when asked what changes he's made so far, Sandoz's top exec Richard Saynor told a German newspaper: "We decided to quit the business with so-called digital therapeutics (for example, apps that help addicts, ed.). While this is a fascinating area, it does not really suit the commercialization of generics." (translated from German) via FiercePharma
  • Swedish specialty pharmaco Orexo has
×

Recent Articles